Skip to main content

Table 1 Inclusion criteria

From: A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix

(i) Pathologically proven squamous cell carcinoma
(ii) Clinical FIGO stage Ib and IIa2 with bulky tumor (>40 mm, assessed by magnetic resonance imaging) or Clinical FIGO stage IIb, IIIa, IIIb and IVa.
(iii) No para-aortic lymph node swelling (≥10 mm) by abdominal computed tomography
(iv) No prior radiation therapy for abdomen
(v) Performance status (Eastern Cooperative Oncology Group): 0-2
(vi) Age: 18 to 70 years old
(vii) Adequate function of bone marrow, kidney and liver
  white blood cell count ≥ 2500 mm3
  neutrophil ≥ 1000 mm3
  hemoglobin ≥ 8.0 g/dl
  platelet count ≥ 75000 mm3
  creatinine ≤ 2.0 mg/dl
  GOT and GPT ≤ 2 times of the upper limit of normal at our institution
  T.Bil ≤ 2 times of the upper limit of normal at our institution)
(viii) Written informed consent